首页> 外文OA文献 >The molecular genetic basis of Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel.
【2h】

The molecular genetic basis of Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel.

机译:以色列的伊拉克犹太人和阿拉伯人中的格兰兹曼血栓性痴呆症的分子遗传基础。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Glanzmann thrombasthenia is an autosomal recessive bleeding disorder characterized by a decrease or absence of functional platelet glycoprotein (GP) IIb-IIIa (alpha IIb beta 3) integrin receptors. Although thrombasthenia is a rare disorder, its occurrence is increased in some regions of the world where intracommunity marriage and consanguinity are commonplace, resulting in increased expression of autosomal recessive traits. We have been studying two populations having an unusually high frequency of Glanzmann disease, Iraqi Jews and Arabs living in Israel, and were able to distinguish the populations on the basis of immunodetectable GPIIIa and platelet surface vitronectin receptor (alpha v beta 3) expression. In this article, we describe molecular genetic studies based on use of the PCR that have allowed us to characterize platelet mRNA sequences encoding GPIIb and GPIIIa from patients in these populations. In six of six Iraqi-Jewish families studied, cDNA sequence analysis identified an 11-base deletion within exon 12 of the GPIIIa gene. This mutation produces a frameshift leading to protein termination shortly before the transmembrane domain of GPIIIa. In contrast, a 13-base deletion encompassing the splice acceptor site of exon 4 of the GPIIb gene was found in three of five Arab kindreds studied. This deletion results in forced alternative splicing to a downstream AG acceptor, producing a 6-amino acid deletion in the GPIIb protein, including a single cysteine residue. These nucleotide sequence variations were exploited to design a rapid, PCR-based oligonucleotide dot-blot hybridization test for both pre- and postnatal diagnosis of Glanzmann disease. These studies demonstrate the heterogeneity of Glanzmann thrombasthenia in different populations, and its homogeneity within geographically restricted populations, and offer insight into the requirements for integrin surface expression.
机译:格兰茨曼性血小板减少症是一种常染色体隐性遗传性出血性疾病,其特征在于功能性血小板糖蛋白(GP)IIb-IIIa(αIIb beta 3)整联蛋白受体减少或不存在。尽管血栓性衰弱是一种罕见的疾病,但在世界上某些社区内婚姻和血缘关系很普遍的地区,其发生率增加,导致常染色体隐性遗传性状的表达增加。我们一直在研究两个患有Glanzmann病的频率很高的人群,即居住在以色列的伊拉克犹太人和阿拉伯人,并且能够根据可免疫检测到的GPIIIa和血小板表面玻连蛋白受体(alpha v beta 3)的表达来区分这些人群。在本文中,我们描述了基于PCR的分子遗传学研究,这些研究使我们能够表征来自这些人群的患者的编码GPIIb和GPIIIa的血小板mRNA。在研究的六个伊拉克-犹太家庭中的六个中,cDNA序列分析确定了GPIIIa基因第12外显子中的11个碱基的缺失。这种突变产生移码,导致蛋白质在GPIIIa的跨膜结构域前不久终止。相比之下,在研究的五个阿拉伯亲戚中,有三个发现了一个包含GPIIb基因第4外显子的剪接受体位点的13个碱基的缺失。该缺失导致与下游AG受体的强制剪接,在GPIIb蛋白中产生6个氨基酸的缺失,其中包括一个半胱氨酸残基。利用这些核苷酸序列变异来设计快速,基于PCR的寡核苷酸斑点印迹杂交测试,以进行格兰兹曼病的产前和产后诊断。这些研究证明了格兰兹曼血栓性衰弱在不同人群中的异质性,以及在地理上受限人群中的同质性,并提供了对整联蛋白表面表达要求的见解。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号